Anisodamine

Summary

Anisodamine (CHEMBL2165224) is a phase-3 clinical-stage small molecule; indicated across 3 conditions including intestinal disorder and toxic shock syndrome.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 3 conditions
• Clinical trials: 3
• Chemistry: 305.4 Da · C17H23NO4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2165224
Name	Anisodamine
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	6918612
Molecular formula	C17H23NO4
Molecular weight	305.4
InChIKey	WTQYWNWRJNXDEG-RBZJEDDUSA-N

SMILES: CN1[C@H]2C[C@@H](C[C@@H]1[C@H](C2)O)OC(=O)[C@H](CO)C3=CC=CC=C3

IUPAC name: [(1R,3S,5R,6S)-6-hydroxy-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] (2S)-3-hydroxy-2-phenylpropanoate

Also known as: (-)-6.beta.-hydroxyhyoscyamine, 6.beta.-hydroxyhyoscyamine, Anisodamine, ANISODAMINE

Parent form; salt/anhydrous children: CHEMBL5483037

Patent coverage: 59 distinct patent families (76 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
intestinal disorder	3	MONDO:0005020	EFO:0009431
toxic shock syndrome	1	MONDO:0001881	EFO:0006834

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 3.

Phase distribution

Phase	Trials
PHASE1/PHASE2	2
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05727163	PHASE2	RECRUITING	FOLFOX Via HAI Plus Intravenous Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Without Bevacizumab in Initially Unresectable RAS-mutated CRLM Patients
NCT02442440	PHASE1/PHASE2	COMPLETED	Anisodamine Critically Ill SeptIc Shock
NCT06045364	PHASE1/PHASE2	COMPLETED	Effect of Glycopyrrolate on Nausea and Vomiting After ERCP Operation

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).